NL300757I2 - - Google Patents

Download PDF

Info

Publication number
NL300757I2
NL300757I2 NL300757C NL300757C NL300757I2 NL 300757 I2 NL300757 I2 NL 300757I2 NL 300757 C NL300757 C NL 300757C NL 300757 C NL300757 C NL 300757C NL 300757 I2 NL300757 I2 NL 300757I2
Authority
NL
Netherlands
Application number
NL300757C
Other languages
Dutch (nl)
Other versions
NL300757I1 (https=
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24630250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300757(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of NL300757I2 publication Critical patent/NL300757I2/nl
Publication of NL300757I1 publication Critical patent/NL300757I1/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D335/00Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
NL300757C 2000-09-05 2015-08-28 NL300757I1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/655,760 US6414016B1 (en) 2000-09-05 2000-09-05 Anti-constipation composition
PCT/JP2001/007628 WO2002020007A1 (en) 2000-09-05 2001-09-04 Cathartic composition

Publications (2)

Publication Number Publication Date
NL300757I2 true NL300757I2 (https=) 2015-12-29
NL300757I1 NL300757I1 (https=) 2015-12-29

Family

ID=24630250

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300757C NL300757I1 (https=) 2000-09-05 2015-08-28

Country Status (25)

Country Link
US (7) US6414016B1 (https=)
EP (2) EP1315485B1 (https=)
JP (3) JP2004508327A (https=)
KR (2) KR100901102B1 (https=)
CN (1) CN100335049C (https=)
AR (2) AR030609A1 (https=)
AT (1) ATE476975T1 (https=)
AU (2) AU2001282615B2 (https=)
BR (1) BRPI0114042B8 (https=)
CA (1) CA2419741C (https=)
CZ (1) CZ304740B6 (https=)
DE (2) DE60131547T2 (https=)
DK (2) DK1857105T3 (https=)
ES (2) ES2347697T3 (https=)
HU (1) HU229319B1 (https=)
IL (2) IL154534A0 (https=)
MX (1) MXPA03001959A (https=)
NL (1) NL300757I1 (https=)
NO (1) NO332701B1 (https=)
NZ (1) NZ524401A (https=)
PT (2) PT1315485E (https=)
RU (1) RU2694361C3 (https=)
TW (1) TWI305147B (https=)
WO (1) WO2002020007A1 (https=)
ZA (1) ZA200301673B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2695274C3 (ru) * 1999-10-15 2020-11-09 Сукампо Аг Новые композиции и способы их стабилизации
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
TWI263505B (en) * 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
DK1562604T3 (da) * 2002-10-23 2012-04-02 Sucampo Ag Prostaglandinforbindelser til behandling af fedme
BRPI0317740B8 (pt) * 2002-12-27 2021-05-25 Sucampo Ag uso do composto 13,14-diidro-15-ceto-16,16-diflúorprostaglandina e1
ATE489096T1 (de) 2003-07-03 2010-12-15 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI348386B (en) * 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
RU2392941C2 (ru) * 2004-09-02 2010-06-27 Сукампо Аг Производные простагландинов для лечения желудочно-кишечного нарушения
DK1841433T3 (da) * 2005-01-27 2012-01-16 Sucampo Ag Præparat til behandling af lidelser i centralnervesystemet
DE602006018583D1 (de) 2005-03-04 2011-01-13 Sucampo Ag Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
WO2006109881A1 (en) * 2005-04-12 2006-10-19 Sucampo Ag Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
EP1984027B1 (en) * 2006-01-24 2015-12-30 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
EP2735566A1 (en) * 2006-02-07 2014-05-28 R-Tech Ueno, Ltd. Method for preparing prostaglandin derivative
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
CN101318948B (zh) * 2008-04-01 2011-04-27 上海天伟生物制药有限公司 鲁比前列酮晶体、其制备方法及用途
US8513441B2 (en) * 2008-08-29 2013-08-20 Alphora Research Inc. Prostaglandin synthesis and intermediates for use therein
JP6113954B2 (ja) * 2008-10-31 2017-04-12 リピッド ファーマシューティカルズ イーエイチエフ. 医薬として使用するための脂肪酸
MX381407B (es) 2008-12-31 2025-03-12 Ardelyx Inc Compuestos y métodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrógeno (nhe) en el tratamiento de trastornos asociados con retención de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2010083597A1 (en) 2009-01-22 2010-07-29 Apotex Pharmachem Inc. Methods of making lubiprostone and intermediates thereof
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
CA2774021A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of opioid receptor antagonist for gastrointestinal tract disorders
WO2011054087A1 (en) * 2009-11-03 2011-05-12 Bernard Charles Sherman Stable pharmaceutical formulations comprising lubiprostone
EP2516412A4 (en) * 2009-12-18 2013-05-29 Apotex Pharmachem Inc PROCESS FOR CLEANING LUBIPROSTON
CA2788334A1 (en) 2010-01-28 2011-08-04 Apotex Pharmachem Inc. Polymorphic forms of lubiprostone
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
HRP20191000T1 (hr) 2013-04-12 2019-09-20 Ardelyx, Inc. Spojevi za vezanje nhe3 i metode inhibiranja transporta fosfata
WO2016161085A1 (en) 2015-04-01 2016-10-06 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
US20170020890A1 (en) * 2015-06-19 2017-01-26 Sucampo Ag Pharmaceutical composition comprising fatty acid derivative
JP6957610B2 (ja) 2016-10-06 2021-11-02 スキャンポ・アーゲーSucampo AG 医薬品用途のための多層ビーズ
MX2019008171A (es) 2017-01-09 2020-02-05 Ardelyx Inc Inhibidores del antiporte mediado por nhe.
MX395405B (es) 2017-01-09 2025-03-25 Ardelyx Inc Compuestos útiles para tratar trastornos del tracto gastrointestinal.
WO2018193572A1 (ja) * 2017-04-20 2018-10-25 株式会社島津製作所 分光光度計
US10422729B1 (en) 2019-03-08 2019-09-24 Biodesix, Inc. Blood sample separation devices and methods

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5720305B2 (https=) 1973-02-28 1982-04-27
US4034003A (en) 1974-04-11 1977-07-05 Ono Pharmaceutical Co., Ltd. 15-Cycloalkyl-prostaglandins
JPS5350141A (en) 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
JPS5391110A (en) 1977-01-20 1978-08-10 Yamanouchi Pharmaceut Co Ltd Novel drug composition for rectal infusion
JPS6022708B2 (ja) 1977-07-14 1985-06-03 小野薬品工業株式会社 プロスタグランジン類似化合物
US4308595A (en) * 1979-12-19 1981-12-29 International Business Machines Corporation Array driver
US4670569A (en) 1981-04-02 1987-06-02 G. D. Searle & Co. 5-fluoro-PGI2 compounds
US4579958A (en) 1983-12-23 1986-04-01 G. D. Searle & Co. 5-fluoro-3-oxa-6,7-didehydro-PGI1 compounds
US4687864A (en) 1983-12-23 1987-08-18 G. D. Searle & Co. 5-fluoro-3-oxa-prostacyclin compounds
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
EP0310305B1 (en) 1987-10-02 1992-07-22 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Cathartics
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 16,16−ジフルオロ−15−オキソ−15−デオキシpge誘導体
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
JP2515442B2 (ja) * 1990-05-01 1996-07-10 株式会社上野製薬応用研究所 膵臓疾患処置剤
JP2938579B2 (ja) 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US5958876A (en) * 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
AUPO665397A0 (en) * 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
US6326360B1 (en) * 1998-03-11 2001-12-04 Grelan Pharmaceuticals Co., Ltd. Bubbling enteric coated preparations
US6471085B1 (en) 1999-10-04 2002-10-29 Anthony J. Gallo Temperature cup
RU2695274C3 (ru) * 1999-10-15 2020-11-09 Сукампо Аг Новые композиции и способы их стабилизации
ES2279467T3 (es) * 2000-07-14 2007-08-16 Henkel Kommanditgesellschaft Auf Aktien Solido ahuecado compartimentado que contiene una porcion de detergente, producto de limpieza o aclarador.
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition

Also Published As

Publication number Publication date
CA2419741C (en) 2010-11-30
TWI305147B (en) 2009-01-11
IL154534A0 (en) 2003-09-17
NO20030996D0 (no) 2003-03-04
NO332701B1 (no) 2012-12-10
JP2004508327A (ja) 2004-03-18
AU2001282615B2 (en) 2006-06-22
ZA200301673B (en) 2003-11-26
US20120022152A1 (en) 2012-01-26
US20030216465A1 (en) 2003-11-20
US8071613B2 (en) 2011-12-06
JP2009114217A (ja) 2009-05-28
MXPA03001959A (es) 2003-06-24
WO2002020007A1 (en) 2002-03-14
KR20080091278A (ko) 2008-10-09
DE60131547T2 (de) 2008-10-23
ES2347697T3 (es) 2010-11-03
AU8261501A (en) 2002-03-22
EP1857105A2 (en) 2007-11-21
JP4684334B2 (ja) 2011-05-18
KR100901102B1 (ko) 2009-06-08
US8748454B2 (en) 2014-06-10
US6414016B1 (en) 2002-07-02
HUP0302422A2 (hu) 2003-10-28
US20030040528A1 (en) 2003-02-27
HU229319B1 (en) 2013-10-28
ATE476975T1 (de) 2010-08-15
NZ524401A (en) 2004-08-27
US8114890B1 (en) 2012-02-14
CZ304740B6 (cs) 2014-09-17
EP1857105B1 (en) 2010-08-11
CA2419741A1 (en) 2002-03-14
EP1315485A1 (en) 2003-06-04
NL300757I1 (https=) 2015-12-29
EP1315485B1 (en) 2007-11-21
RU2694361C2 (ru) 2019-07-12
HUP0302422A3 (en) 2005-02-28
KR100918223B1 (ko) 2009-09-21
ES2296786T3 (es) 2008-05-01
US20120237598A1 (en) 2012-09-20
BRPI0114042B8 (pt) 2021-05-25
AR030609A1 (es) 2003-08-27
JP2009286806A (ja) 2009-12-10
AR100291A2 (es) 2016-09-28
RU2694361C3 (ru) 2020-07-20
NO20030996L (no) 2003-05-02
BRPI0114042B1 (pt) 2016-11-08
KR20030029919A (ko) 2003-04-16
RU2694361C9 (ru) 2019-12-25
US20140235665A1 (en) 2014-08-21
IL154534A (en) 2010-04-29
PT1315485E (pt) 2008-01-23
DK1857105T3 (da) 2010-09-20
DE60142810D1 (de) 2010-09-23
CN1655776A (zh) 2005-08-17
DE60131547D1 (de) 2008-01-03
EP1857105A3 (en) 2008-03-05
US20050222195A1 (en) 2005-10-06
US6610732B2 (en) 2003-08-26
CN100335049C (zh) 2007-09-05
DK1315485T3 (da) 2008-03-03
BR0114042A (pt) 2003-07-22
PT1857105E (pt) 2010-10-08

Similar Documents

Publication Publication Date Title
NL300757I2 (https=)
BE2014C019I2 (https=)
BE2013C048I2 (https=)
BE2012C026I2 (https=)
BRPI0113420B8 (https=)
JP2003520463A5 (https=)
AU2000236815A8 (https=)
JP2003522326A5 (https=)
JP2001290811A5 (https=)
JP2001171249A5 (https=)
JP2002119645A5 (https=)
JP2002130740A5 (https=)
JP2002055152A5 (https=)
JP2002128267A5 (https=)
JP2000261689A5 (https=)
JP2001249344A5 (https=)
JP2001287188A5 (https=)
JP2002140649A5 (https=)
BRPI0003419A (https=)
BY5768C1 (https=)
CN3141399S (https=)
CN3135921S (https=)
CN3141410S (https=)
CN3141406S (https=)
CN3141860S (https=)